Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Clinical trial NCT06021678 · RECRUITING
Trial details
- NCT number
- NCT06021678
- Sponsor
- Guangzhou Excelmab Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-12
- Primary completion
- 2025-10-01
- Enrollment
- 415
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.